InspireMD (NSPR) reported second-quarter 2026 revenue of $1.771 million, down 0.4% from $1.778 million a year earlier. The company recorded a net loss of $14.324 million, or $0.17 per basic and diluted share, compared with a $13.151 million loss, or $0.26 per share, in the prior-year quarter.
International revenue rose 21% to $2.122 million, while U.S. revenue was negative $351,000 after $734,000 in customer credits related to the voluntary recall of the CGuard Prime 135 cm delivery system.
- Second-quarter gross loss was $774,000, including a $612,000 inventory impairment and recall-related customer credits.
- Operating expenses increased 2.5% to $13.671 million.
- Cash, cash equivalents and marketable securities totaled $30.421 million at June 30, 2026.
- The company initiated savings actions after quarter-end that are expected to generate approximately $9 million in annual savings.
- InspireMD said it anticipates FDA decisions later in 2026 for its CGuard Prime 80 cm implant for TCAR procedures and its original CGuard platform for traditional carotid stenting.
$NSPR Insider Trading Activity
$NSPR insiders have traded $NSPR stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NSPR stock by insiders over the last 6 months:
- PAUL STUKA has made 3 purchases buying 35,000 shares for an estimated $34,825 and 0 sales.
- MARVIN SLOSMAN (CEO and President) purchased 21,000 shares for an estimated $25,200
- SHANE THOMAS GLEASON (Chief Commercial Officer) sold 22,778 shares for an estimated $23,005
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NSPR Hedge Fund Activity
We have seen 16 institutional investors add shares of $NSPR stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 1,951,514 shares (-92.9%) from their portfolio in Q2 2026, for an estimated $1,366,254
- ABERDEEN GROUP PLC added 525,000 shares (+16.5%) to their portfolio in Q2 2026, for an estimated $367,552
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 114,085 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $79,870
- SCHONFELD STRATEGIC ADVISORS LLC added 99,275 shares (+inf%) to their portfolio in Q2 2026, for an estimated $69,502
- RENAISSANCE TECHNOLOGIES LLC added 95,223 shares (+540.8%) to their portfolio in Q2 2026, for an estimated $66,665
- CREATIVE PLANNING added 89,250 shares (+452.7%) to their portfolio in Q2 2026, for an estimated $62,483
- MILLENNIUM MANAGEMENT LLC removed 74,746 shares (-66.5%) from their portfolio in Q2 2026, for an estimated $52,329
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
